Clinical Trials | December 19, 2025
Gilead’s new HIV therapy shows promising Phase 3 results
The study found BIC/LEN to be statistically non-inferior to BIKTARVY, Gilead’s current standard-of-care therapy
The study found BIC/LEN to be statistically non-inferior to BIKTARVY, Gilead’s current standard-of-care therapy
The expansion includes a larger technical and service team and increased local procurement
Patients with BRCA mutations often face aggressive disease and poor prognosis
Qfitlia is the first antithrombin (AT)-lowering therapy approved for routine prophylaxis in hemophilia
Alphyn is developing Zabalafin Hydrogel as the first therapy to simultaneously tackle the interconnected drivers of AD
In her previous roles, Menon led significant digital transformation efforts, implementing predictive analytics, automation
Glenmark's Leucovorin Calcium for Injection USP, 350 mg/vial Single-Dose Vial is bioequivalent and therapeutically equivalent to the reference listed drug
Formycon AG will develop, register, manufacture and supply the product, while Zydus Lifesciences Global FZE, United Arab Emirates will be responsible for the commercialization of FYB206 in the defined territories
The agreement pairs Croda’s global footprint and “smart science” approach with Amino’s precision manufacturing capabilities
_256_384.jpg)
Tirzepatide is the first and only dual agonist glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
